2026-09-26 05:16:20 UTC#371858updateconfirmedanalysis
Eli Lilly (LLY) stock news
Eli Lilly (LLY) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-09-26 01:00:08 UTC#371552duplicateconfirmedanalysis
Analysts view InnoCare-Eli Lilly deal as sign of China's evolving biotech innovation landscape
2026-09-25 21:41:00 UTC#371225duplicateconfirmednews
FDA grants expanded label approval for Eli Lilly's Olumiant in pediatric alopecia patients
dow_jonesimportance 0.30trust 0.90Eli Lilly and Company +0.40Food and Drug Administration +0.30baricitinib +0.50+1 entities
2026-09-25 21:26:00 UTC#371169newconfirmednews
FDA approves Eli Lilly's Olumiant for pediatric patients 12 and older with severe alopecia areata
dow_jonesimportance 0.40trust 0.90Eli Lilly and Company +0.40U.S. Food and Drug Administration +0.20baricitinib +0.40+1 entities
2026-09-25 15:14:02 UTC#369594duplicateconfirmednews
Eli Lilly ordered to pay Nektar $90 million in Rezpeg breach of contract case
reutersimportance 0.40trust 0.90Eli Lilly and Company -0.10Nektar Therapeutics +0.30Dermira, Inc. 0+1 entities
2026-09-25 13:52:00 UTC#369085duplicateconfirmednews
Nektar Therapeutics wins $90 million jury verdict against Eli Lilly in rezpegaldesleukin breach of contract suit
dow_jonesimportance 0.30trust 0.90Nektar Therapeutics +0.60Eli Lilly and Company -0.40rezpegaldesleukin 0+2 entities
2026-09-25 13:47:09 UTC#369136duplicateconfirmednews
Nektar Therapeutics shares rise 3.6% following $90M jury verdict against Eli Lilly
yahooimportance 0.30trust 0.70Nektar Therapeutics, Inc. +0.50Eli Lilly and Company -0.40rezpegaldesleukin 0
2026-09-25 13:37:00 UTC#369043duplicateconfirmednews
Nektar Therapeutics wins $90 million jury verdict against Eli Lilly in rezpegaldesleukin breach of contract case
dow_jonesimportance 0.30trust 0.90Nektar Therapeutics +0.60Eli Lilly and Company -0.50rezpegaldesleukin 0+2 entities
2026-09-25 11:26:18 UTC#368216duplicateconfirmednews
Nektar Therapeutics shares rise 5% following $90M jury verdict against Eli Lilly
2026-09-25 11:03:19 UTC#368137duplicateconfirmednews
Nektar Therapeutics wins $90M jury verdict against Eli Lilly in rezpegaldesleukin breach of contract case
tradingviewimportance 0.40trust 0.70Nektar Therapeutics, Inc. +0.60Eli Lilly and Company -0.50rezpegaldesleukin 0+1 entities
2026-09-25 11:02:51 UTC#368138duplicateconfirmednews
Jury finds Eli Lilly breached license agreement with Nektar Therapeutics, awards $90 million in damages
2026-09-25 11:00:01 UTC#368108newconfirmedanalysis
Analysts weigh competitive advantages of Eli Lilly over Novo Nordisk in obesity drug market
2026-09-25 00:38:10 UTC#366362newconfirmednews
Nektar Therapeutics awarded $90 million in breach of contract lawsuit against Eli Lilly over Rezpeg drug
Open sourceimportance 0.60trust 0.70Nektar Therapeutics +0.50Eli Lilly and Company -0.40Rezpeg 0+1 entities
2026-09-24 19:18:52 UTC#365042newconfirmednews
Eli Lilly shares rise 3.6% to $1,192.91 amid intensifying competition in $100 billion obesity drug market
2026-09-24 19:06:08 UTC#365039duplicateconfirmedanalysis
CNBC Investing Club reviews Starbucks turnaround strategy and highlights Eli Lilly developments
2026-09-24 12:04:42 UTC#362494duplicateconfirmednews
Eli Lilly Receives FDA Approval for Once-Weekly Onswik Insulin for Type 2 Diabetes
zerodha pulseimportance 0.30trust 0.70Eli Lilly and Company +0.60Food and Drug Administration +0.50Onswik +0.60+1 entities
2026-09-24 11:30:14 UTC#361924duplicateconfirmednews
US FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes
reutersimportance 0.30trust 0.90Eli Lilly and Company +0.60U.S. Food and Drug Administration +0.20Type 2 diabetes 0
2026-09-24 11:25:52 UTC#361906duplicateconfirmednews
US FDA approves Eli Lilly's once-weekly basal insulin Onswik for type 2 diabetes
reutersimportance 0.40trust 0.90Eli Lilly and Company +0.60U.S. Food and Drug Administration +0.20Onswik +0.60
2026-09-24 10:47:36 UTC#361666duplicateconfirmednews
FDA Approves Eli Lilly's Once-Weekly Basal Insulin Onswik for Type 2 Diabetes
reutersimportance 0.60trust 0.90Eli Lilly and Company +0.60U.S. Food and Drug Administration +0.20Onswik +0.60
2026-09-24 10:45:00 UTC#361649duplicateconfirmedpress release
FDA approves Eli Lilly's Onswik (insulin efsitora alfa-gobe) as once-weekly basal insulin for type 2 diabetes
pr_newswireimportance 0.70trust 1.00Eli Lilly and Company +0.70U.S. Food and Drug Administration +0.50Onswik +0.70